247 results on '"Moskowitz, Samuel M"'
Search Results
2. Rhesus θ-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of Pseudomonas aeruginosa
3. Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in People With Cystic Fibrosis and at Least OneF508delAllele: 144-Week Interim Results From a 192-Week Open-label Extension Study
4. Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor
5. The CF-CARES primary palliative care model: A CF-specific structured assessment of symptoms, distress, and coping
6. Carbon Sources Tune Antibiotic Susceptibility in Pseudomonas aeruginosa via Tricarboxylic Acid Cycle Control
7. Lung function and microbiota diversity in cystic fibrosis
8. Second generation modifiers of colistin resistance show enhanced activity and lower inherent toxicity
9. Development and evaluation of a palliative care curriculum for cystic fibrosis healthcare providers
10. Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study
11. Correction to: Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor
12. Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating or residual function mutation
13. The Role of Pseudomonas Lipopolysaccharide in Cystic Fibrosis Airway Infection
14. Sustained Pulmonary Delivery of a Water-Soluble Antibiotic Without Encapsulating Carriers
15. Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation : A Phase 3b, Randomized, Placebo-controlled Study
16. Site-specific activity of the acyltransferases HtrB1 and HtrB2 in Pseudomonas aeruginosa lipid A biosynthesis
17. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial
18. Unique Lipid a Modifications in Pseudomonas aeruginosa Isolated from the Airways of Patients with Cystic Fibrosis
19. Genetic Adaptation by Pseudomonas aeruginosa to the Airways of Cystic Fibrosis Patients
20. Triple Therapy for Cystic Fibrosis Phe508del –Gating and –Residual Function Genotypes
21. Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study.
22. Triple Therapy for Cystic Fibrosis Phe508del–Gating and –Residual Function Genotypes
23. Case 25-2015: An 8-Year-Old Girl with a Chest-Wall Mass and a Pleural Effusion
24. Nitrite modulates bacterial antibiotic susceptibility and biofilm formation in association with airway epithelial cells
25. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele
26. Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients
27. A NOVEL THERAPEUTIC APPROACH THAT TARGETS PERSISTER CELLS: S4.4
28. Azithromycin May Antagonize Inhaled Tobramycin When Targeting Pseudomonas aeruginosa in Cystic Fibrosis
29. A divergent Pseudomonas aeruginosa palmitoyltransferase essential for cystic fibrosis-specific lipid A
30. Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial
31. COLISTIN RESISTANCE: AN EMERGING THREAT TO A LAST LINE THERAPY: S17.1
32. Additional file 1 of Lung function and microbiota diversity in cystic fibrosis
33. Additional file 5 of Lung function and microbiota diversity in cystic fibrosis
34. Additional file 2 of Lung function and microbiota diversity in cystic fibrosis
35. Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment
36. The Pseudomonas aeruginosa lipid A deacylase: selection for expression and loss within the cystic fibrosis airway
37. PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A
38. Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection
39. Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia
40. Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
41. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
42. BIOFILM SUSCEPTIBILITY TESTING: DOES IT HAVE A ROLE IN CF MICROBIOLOGY?: S11.3
43. Shifting Patterns of Inhaled Antibiotic Use in Cystic Fibrosis
44. Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection
45. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One Allele.
46. Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles
47. Effects of a primary palliative care intervention on quality of life and mental health in cystic fibrosis
48. Comparative Metabolomics and Transcriptomics Reveal Multiple Pathways Associated with Polymyxin Killing in Pseudomonas aeruginosa
49. Advance Care Planning Experiences and Preferences among People with Cystic Fibrosis
50. VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.